Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Dodwell

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Breast Cancer Research and Treatment|March 12, 2011
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancerR Coleman, E Woodward, J Brown, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 12, 2025
Discrepancy between mammographic and pathological sizing of screen-detected DCIS: Risk factors and impact on ipsilateral recurrence ratesC C Kirwan, B Hilton, K Clements, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 12, 2024
The Assisi think tank focus review on postoperative radiation for lobular breast cancerO Kaidar-Person, I Ratosa, P Franco, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 5, 2019
The SMALL Trial: A Big Change for Small Breast CancersJ Morgan, S Potter, N Sharma, et al.
Journal of Bone Oncology|December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)R E Coleman, M Collinson, W Gregory, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European PanelP Hadji, R E Coleman, C Wilson, et al.
Lancet (London, England)|February 20, 2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Breast Cancer Research and Treatment|March 12, 2011
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancerR Coleman, E Woodward, J Brown, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 12, 2025
Discrepancy between mammographic and pathological sizing of screen-detected DCIS: Risk factors and impact on ipsilateral recurrence ratesC C Kirwan, B Hilton, K Clements, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 12, 2024
The Assisi think tank focus review on postoperative radiation for lobular breast cancerO Kaidar-Person, I Ratosa, P Franco, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 5, 2019
The SMALL Trial: A Big Change for Small Breast CancersJ Morgan, S Potter, N Sharma, et al.
Journal of Bone Oncology|December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)R E Coleman, M Collinson, W Gregory, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European PanelP Hadji, R E Coleman, C Wilson, et al.
Lancet (London, England)|February 20, 2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.
Pageof 9